Overview

Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

Status:
Recruiting
Trial end date:
2022-08-30
Target enrollment:
Participant gender:
Summary
The main purpose of the study is to evaluate safety and efficacy of Alkotinib capsule in patients with ALK-positive non-small cell lung cancer previously treated with crizotinib.While exploring the relationship between biomarkers and drug efficacy and safety.
Phase:
Phase 2
Details
Lead Sponsor:
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Treatments:
Crizotinib